In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
News|Podcasts|March 26, 2026
Pharma Pulse: FDA Warns ImmunityBio Over Misleading Claims and MedImpact’s New GLP-1 Programs
Author(s)Stephen Appezzato
In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and MedImpact launches new solutions to address the skyrocketing employer costs of GLP-1 weight management therapies.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.
- First, the FDA’s Office of Prescription Drug Promotion issued a warning letter to ImmunityBio for misleading advertisements regarding its cancer therapy, Anktiva. Regulators found that promotional materials
overstated the drug's efficacy —implying it could cure cancer or prevent recurrence—while misrepresenting its administration as a subcutaneous injection rather than its approved intravesical-only route. Following the regulatory action, ImmunityBio shares fell 26%. - Next, MedImpact has launched GLP-1 Benefit 360 and GLP-1 Direct Fund to address a
surge in employer per-member-per-month costs for weight management therapies. These models aim to provide predictable pricing and integrated clinical support, including access to registered dietitians, to combat high discontinuation rates and prevent metabolic rebound.
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
With a lawsuit, a House delay bill and drugmaker intervention motions in play, here's where HRSA's 340B rebate pilot stands ahead of Jan. 1.
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
FDA’s final guidance on prescription drug use-related software clarifies when companion app content is labeling, promotion or belongs in the PI.
Epic's Prescription Marketplace, due summer 2027, will show pharmacy cash prices next to insured costs before a prescription is sent.
Advertisement
Advertisement